# Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

> **NCT03790670** · PHASE1 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 7 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** sargramostim

## Key facts

- **NCT ID:** NCT03790670
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-30
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03790670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03790670, "Biomarker Assessments of Leukine During Treatment of Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03790670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*